PT-141 vs Melanotan II: what the published research shows

At a glance

Same framework, a different ending

In sequence notation, Melanotan II is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, while PT-141 is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. The important difference is the ending, not an extra amino acid or an entirely new peptide chain. (King et al., melanocortin research review)

Their reference molecular weights are correspondingly close: 1024.2 g/mol for Melanotan II and 1025.2 g/mol for bremelanotide. These figures describe the free peptides, so the chemical form stated on a laboratory report matters. (PubChem: Melanotan II) (PubChem: bremelanotide)

Receptors: why the story is more than skin deep

Melanocortin receptors are a family of signalling switches. MC1R is associated with pigmentation, while MC3R and MC4R are involved in central nervous system pathways. The overlap helps explain why the early Melanotan II experiments recorded effects beyond the pigmentation researchers were investigating. (King et al., melanocortin research review)

It would be too simple to label one peptide a “skin-only” compound and the other a “brain-only” compound. The Vyleesi label describes bremelanotide as a nonselective agonist at several melanocortin receptor subtypes, with MC1R and MC4R binding most relevant at therapeutic levels. It also states that the mechanism by which Vyleesi improves HSDD is unknown. (Vyleesi prescribing information)

Two different research paths

Melanotan II's early human record includes a 1996 phase 1 pilot in three male volunteers. Two showed increased pigmentation, and the investigators also recorded nausea, fatigue and sexual responses. As a three-person pilot, it is a starting point for questions, not a demonstration of broad safety or an established treatment. (Dorr et al., Life Sciences (1996))

Bremelanotide later underwent a much larger clinical programme. The two RECONNECT trials randomised 1,267 premenopausal women with HSDD to bremelanotide or placebo for a 24-week treatment period. Both met their prespecified primary endpoints for questionnaire-measured desire and distress associated with low desire; the number of satisfying sexual events, a separate secondary endpoint, did not differ significantly. (Kingsberg et al., RECONNECT trials (2019))

The programme led to Vyleesi's initial US approval in 2019 for acquired, generalised HSDD in premenopausal women, under the conditions in its label. It is not approved under that label for men, postmenopausal women or sexual performance enhancement. (Vyleesi prescribing information)

Where the research stands

The useful distinction is the quality and scope of evidence, not which peptide sounds more appealing. RECONNECT studied a defined medicinal formulation in a defined population, and the trial publication discloses commercial sponsorship. Those results cannot establish the quality or clinical suitability of a separately supplied research product. (Kingsberg et al., RECONNECT trials (2019)) (Vyleesi prescribing information)

The approved medicine also has important safety qualifications. Its label reports nausea in 40% of treated participants, warns about transient blood pressure increases and focal hyperpigmentation, and contraindicates use in people with uncontrolled hypertension or known cardiovascular disease. (Vyleesi prescribing information)

For Australian readers, the TGA's August 2026 alert states that Melanotan II is prescription-only, is not approved as a tanning agent, and has no product included in the Australian Register of Therapeutic Goods. The alert also explains that supply and advertising of unapproved therapeutic goods are prohibited unless a relevant exemption applies. (TGA: Melanotan II safety alert (2026))